Connect with us

BUSINESS

Claritas Pharmaceuticals Inc (OTCMKTS: KALTF) Announced Data Displaying the Effectiveness its R-107 compound has on Covid-19 Patients

Published

on

Claritas Pharmaceuticals Inc (OTCMKTS: KATLF) announced that clinicians from the Royal Brompton and Harefield NHS Foundation recently published a study that validated the potential of Claritas’ R-107, nitric oxide-releasing component, as a potential therapeutic treatment for Covid-19 and coronavirus infections. In the research study, Covid-19 pneumonia patients who inhaled nitric oxide significantly improved their oxygen levels.

The Royal Brompton and Harefield NHS Foundation study were one of a kind. It was the most extensive research study of its kind globally. In this clinical study, about thirty-five patients with coronavirus pneumonia who were relying on ventilation systems were told to inhale the R-107 compound as part of their medical care routine when they weren’t responding to the conventional standard treatments.

The Science of the R-107 Compound

This is a nitric oxide-releasing component designed by Claritas to help possibly treat Covid-19 pneumonia. Following R-107’s administration, the compound makes its way into your bloodstream then systematically releases nitric oxide slowly over the course of the next twenty-four hours. The body itself, however, can produce nitric oxide on its own. It’s a natural molecule containing antiviral properties that play a vital role in the human body’s natural defense system. When the body detects a viral threat, white blood cells are then deployed to where the infection is, and then they start releasing nitric oxide in bursts. This nitric oxide then inactivates the virus and blocks it from replicating and spreading further.

Nitric oxide is well-known to be able to treat very many different viruses, including the so-called RNA ones. The Covid-19 SARS-CoV-2 is one of those RNA viruses. Other RNA viruses are measles, rabies, West Nile fever, hepatitis E, hepatitis C and the common cold. The hardest thing about Nitric oxide is its administration. It’s a gas that needs to be inhaled. This means that you’ll need trained respiratory therapists and CPAP-like devices.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Curaleaf Holdings Inc (OTCMKTS: CURLF) Announces Revenue of $312 Million in Second Quarter of 2021

Published

on

Curaleaf Holdings Inc (OTCMKTS: CURLF) is a top global cannabis-based consumer products corporation that recently announced a $312 million revenue in Q2 F21. The company provided all this information in U.S dollars.

Key Highlights 

Total revenue recorded in Q2 F21 was $312 million, representing a year-over-year increase of 166%, compared to the $117 million reported in the same quarter of the previous fiscal year. When they excluded international business operations, total revenue came to $307 million. In the second quarter of this fiscal year, the company opened a total of five new cannabis and CBD-based dispensaries. This included a second New Jersey location, one in Illinois, two in Pennsylvania, and an adult-use retail store in Maine (the first of its kind), which pushed the company’s total to 107 dispensaries by the end of the quarter.

The retail revenue recorded by the company was $222 million, which represented a 235% year-over-year growth and 18.4% sequential growth. Robust growth in the company’s retail business operations was mainly driven by the increase in repeat clients/customers and new customer acquisition. Retail revenue made up for 71% of the company’s total revenue.

Wholesale revenue came to $89 million, which was 29% of all its revenue. Strong wholesale operation growth was driven primarily by the boost in sales productivity and new accounts additions. Gross profit recorded in this quarter was $155 million, which was a lot more than the $43 million they recorded in the same quarter of the previous fiscal year.

Senior Management

CurAleaf’s Executive Chairman, Boris Jordan, said that July is when the United States introduced the most comprehensive cannabis-related reform that the Federal government has ever proposed. Combined with the significant investments the company is making in distribution, cultivation, and production and United States state-level liberation, the CEO said that they’re developing a robust foundation for future growth. He claimed that this includes expanding their Connecticut, New Jersey, and New York markets in the short-term.  

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Canopy Growth Corp (NASDAQ: CGC) Records Revenue Growth of 23% in Q1 F22

Published

on

Canopy Growth Corporation (NASDAQ: CGC) is a global, diversified CBD-based and cannabis consumer product corporation that focuses on strengthening communities, ending prohibition, and improving lives by showing the true power of cannabis recently reported revenue growth of 23% in Q1 F22.

Senior Management

Canopy’s Chief Executive Officer, David Klein, said that with a robust foundation and right strategy in place, they’re confident in their ability to achieve long-term success as the company’s brands and products show how appealing they are to the consumers in their core markets. He continued to say that while they’re encouraged by the United States’ regulatory advancements, the company isn’t waiting and will continue to scale the business efforts on Canadian and U.S. soil with a new, innovative, and exciting product pipeline set for the fiscal quarters ahead.

The CEO said that the company continues to boost operational efficiencies and cost savings across the board and are quite on track to hit their target range of $150 to $200 million in the next fiscal year. He confirmed that they’re looking forward to scaling their new and improved operating model as they push their profitability goals forward.

Key Highlights 

Recorded a $136 million net revenue in Q1 F22, a 23% increase from what they reported in the same quarter of the previous fiscal year. This is was largely due to the significant double-digit growth the company experienced across cannabis products in Canada and other CBD-related consumer products. The cannabis net revenue came to about $93 million in this quarter being highlighted, which represented a 17% increase from the same quarter of the previous fiscal year.

There was a decline of 17% in total operating expenses in Q2 F22. Year-over-year reductions in R&D (research and development) and G&A (general and administrative) are one of the things that helped drive the decline of total operating expenses in this quarter. The company also reported $390 million in net earnings in Q2 F22 and $64 million Adjusted EBITDA in the same quarter.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

GrowGeneration Corp (NASDAQ: GRWG) Reports $125.9 Million Revenue in Q2 F21

Published

on

GrowGeneration Corp (NASDAQ: GRWG) is a vast chain of organic garden and specialty hydroponic facilities with fifty-eight centers across twelve states, which recently announced record revenue of $125.9 million in Q2 F21. This was way more than the $43.5 million they recorded in the same quarter of the previous fiscal year. GrowGeneration also reported a record pre-tax GAAP net income of roughly $9.6 million in the same quarter, more than the $2.7 million they had in the same quarter of the previous fiscal year. In addition, they recorded a $0.11 diluted earnings per/share, tax expense included in the same quarter.

Senior Management

The company’s Chief Executive Officer and Co-Founder, Darren Lampert, said that GrowGeneration’s team managed to deliver an exceptionally robust second quarter, with a 190% increase in revenues compared to what they recorded in the same quarter of the previous financial year. The entire company managed to bring in more revenue in Q1 F21 than it did the whole of the last financial year. The CEO said that they closed twelve acquisitions this financial year, adding a total of twenty hydroponic retail sites, bringing the company’s capacity to fifty-eight. He further claimed that their ability to both buy and attract the country’s largest hydroponic operators was again evident when they signed the nation’s third-largest hydroponic operator, HGS Hydro. It looks like the strategies that were implemented by the company many quarters ago are starting to help boost margins.

Mr. Lampert said that they increased their inventory positions in all the key product sectors so that they could be well-prepared for price increases. The company also expanded its private-label purchases. He claimed that their proprietary and private-label products now make up roughly 7% of their overall sales. He said that he was both encouraged and proud with their gross profit margin, which happened despite container cost increases, supply chain interruptions, and port delays.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories